摘要
目的探讨多西他赛+奥沙利铂+替吉奥(DSOX)方案和多西他赛+顺铂+氟尿嘧啶(DCF)方案治疗晚期胃癌的效果及对血清可溶性白细胞介素-2受体(sIL-2R)、分泌型糖蛋白(DKK-1)表达的影响。方法依据纳入和排除标准,本研究共纳入148例晚期胃癌患者,依据治疗方案分为DSOX组(n=80)和DCF组(n=68),观察组给予DSOX方案治疗,对照组采用DCF方案治疗。比较两组患者的临床疗效、预后情况、血清肿瘤标志物水平及不良反应发生情况。结果DSOX组患者的临床疗效明显优于DCF组患者,差异有统计学意义(P<0.01),DSOX组患者的治疗总有效率为51.25%。化疗后,两组患者血清sIL-2R、DKK-1水平均低于本组化疗前,且DSOX组患者血清sIL-2R、DKK-1水平均低于DCF组患者,差异均有统计学意义(P<0.05)。DSOX组患者中位总生存时间为12.00个月,明显长于DCF组患者的8.00个月;中位无进展生存时间为9.00个月,明显长于DCF组患者的5.00个月,差异均有统计学意义(P<0.01)。两组患者3~4级白细胞降低、血小板减少、恶心呕吐、腹泻、脱发、周围神经毒性不良反应发生率比较,差异均无统计学意义(P>0.05)。结论与DCF方案相比,DSOX方案治疗晚期胃癌的效果较好,可明显降低血清sIL-2R、DKK-1水平。
Objective To investigate the effect of docetaxel+oxaliplatin+tegio(DSOX regimen)and docetaxel+cisplatin+fluorouracil(DCF regimen)on advanced gastric cancer and expression of soluble interleukin-2 receptor(sIL-2R)and Dickkopf-1(DKK-1).Method A total of 148 patients with advanced gastric cancer were enrolled in this study according to the inclusion and exclusion criteria,and they were divided into DSOX group(n=80)and DCF group(n=68)based on the treatment regimen.The observation group was treated with DSOX regimen,while the control group was treated with DCF regimen.The clinical efficacy,prognosis,serum tumor markers and adverse events of the two groups were compared.Result The clinical efficacy of the DSOX group was better than that of the DCF group,and the difference was statistically significant(P<0.01).The overall response rate of patients in the DSOX group was 51.25%;After chemotherapy,the serum sIL-2R and DKK-1 levels of both groups were lower than before chemotherapy,and serum sIL-2R and DKK-1 levels of DSOX group were lower than those of the DCF group,and the differences were statistically significant(P<0.05);the median overall survival of patients in the DSOX group was 12.00 months,which was significantly longer than that of the DCF group,whose duration was 8.00 months(P<0.05).The median progression-free survival was 9.00 months,which was significantly longer than 5.00 months in the DCF group,and the difference was statistically significant(P<0.01).The incidence of grade 3 to 4 leukopenia,thrombocytopenia,nausea and vomiting,diarrhea,alopecia,and peripheral neurotoxic adverse events between the two groups showed on significantly different(P>0.05).Conclusion The DSOX regimen has a better effect in the treatment of advanced gastric cancer compared with the DCF regimen and can significantly reduce the serum sIL-2R and DKK-1 levels.
作者
梁红
魏可新
范晶晶
LIANG Hong;WEI Kexin;FAN Jingjing(Deartment of Medical Oncology,Huludao Central Hospital,Huludao 125000,Liaoning,China)
出处
《癌症进展》
2020年第20期2110-2113,共4页
Oncology Progress
